Legal Action Announced As Investors in PROCEPT BioRobotics Face Substantial Losses

A recent announcement by Hagens Berman Sobol Shapiro LLP highlights a significant situation for investors of PROCEPT BioRobotics Corporation. As reported, a securities class action lawsuit has been filed concerning substantial losses that many investors have incurred over the past couple of years. The firm is reaching out to those who've invested in PROCEPT BioRobotics (NASDAQ: PRCT) amid claims that the company's communications regarding its sales performance have not been transparent, leading to surprising underperformance and a serious impact on investors’ finances.

Understanding the Background of the Case

The essence of the lawsuit revolves around the company’s single-use handpiece sales, which are integral to its proprietary Aquablation therapy, used to treat patients with an enlarged prostate. Between February 28, 2024, and February 25, 2026, investors were reportedly misled about the company’s performance. The lawsuit claims that PROCEPT’s management provided misleading information about their handpiece sales practices in the U.S., suggesting a growth trajectory that, as it turns out, was not accurate.

The complaint asserts that PROCEPT unlocked an excess inventory situation by promoting bulk discounts at the end of quarters, leading customers to order more than needed. This tactic artificially inflated sales figures as the company rushed to meet what were perceived to be soaring demands, essentially pulling sales forward from future periods at the expense of long-term financial stability. Consequently, investors only started to grasp the reality through a series of announcements that revealed a different financial picture than what had been communicated.

Key Developments in the Investigation

The equity of this case grew more substantial following several disclosures. In Q2 of 2025, PROCEPT reported that its handpiece sales had dropped unexpectedly, missing consensus estimates drastically. The situation worsened with subsequent reports indicating continual declines in sales and alarming statements from management reflecting issues with customer inventory management.

After various partial disclosures shaking investor confidence, it was shown that handpiece sales in the U.S. significantly outpaced the number of procedures conducted, accumulating over 10,000 units in excess customer inventory. The management’s statement about terminating the bulk order discount program also raised eyebrows, hinting at poor sales strategies in managing client inventories. This revelation prompted a severe decline in PROCEPT's stock price, resulting in a reduction of over 48% since previous highs noted during August 2025.

Call to Action for Affected Investors

In response to these developments, Hagens Berman has urged investors who have faced substantial financial losses attributed to these actions to come forward. The firm is seeking information from any individuals who might assist with the case and provides a support framework, especially for those who may already possess significant information regarding the company.

The legal team emphasizes the violation of federal securities laws regarding communication and business conduct, noting that these deceptive practices could have been intentional to maintain a favorable image of PROCEPT among investors.

In light of this situation, if you have previously invested in PROCEPT BioRobotics and suffered losses, it is crucial to act promptly. Interested investors can consult the firm's attorneys and have the opportunity to join the class action lawsuit which aims to put forth a strong case against the alleged misleading practices of PROCEPT.

For those considering becoming whistleblowers and who possess non-public information about PROCEPT’s internal practices, the firm points out that there are options available for providing crucial data, potentially leading to significant rewards under the SEC Whistleblower program.

A Future of Corporate Accountability

Hagens Berman Sobol Shapiro LLP aims to ensure corporate accountability, shedding light on wrongdoing in corporate practices and defending the rights of investors. With over $2.9 billion secured for clients in similar cases, the firm offers a structured approach toward reclaiming losses suffered by investors in contexts of corporate negligence. Remaining abreast of updates on this case can be vital for affected individuals.